Friday, August 12, 2022
    HomeHealthMedicare proposes to restrict coverage of Biogen Alzheimer's drug

    Medicare proposes to restrict coverage of Biogen Alzheimer’s drug


    Hello, everybody, and welcome to the center of the week. You made it this far, so why not proceed, sure? Maybe a cup or two of stimulation is so as. Our selection right now is stroopwafel. As you realize, a prescription just isn’t required. So be at liberty to indulge as you assault the laundry record of conferences and deadlines that await. In the meantime, we now have as soon as once more assembled a listing of tidbits so that you can peruse and make it easier to in your approach. Hope you’ve a smashing day and, as all the time, do drop us a line once you hear one thing attention-grabbing. …

    Medicare plans to cowl the controversial Biogen (BIIB) Alzheimer’s drug, however just for sure sufferers enrolled in medical trialsSTAT tells us. The proposed transfer would probably imply some sufferers won’t be able to entry the drug, referred to as Aduhelm, which is the primary Alzheimer’s remedy permitted in practically 20 years. Because it was endorsed final June by the U.S. Meals and Drug Administration, medical doctors and scientists have raised questions on whether or not it truly works, authorities watchdogs have begun investigating whether or not the FDA adopted correct approval procedures, and coverage specialists have questioned whether or not it’s efficient sufficient to justify its $28,000 price ticket.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts